Company Overview

MedPlus Health Services Limited reported strong financial performance for FY 2025-26 with consolidated revenue growth of 12.33% to ₹68,924.66 million and profit after tax increasing 46.18% to ₹2,196.06 million. The company operates primarily in pharmaceutical retail and diagnostic services across 13 states and 1 union territory.

Financial Performance

Consolidated Financial Highlights

  • Revenue from Operations: ₹68,924.66 million (12.33% growth from FY25)
  • Profit Before Tax: ₹2,753.30 million (50.21% growth)
  • Profit After Tax: ₹2,196.06 million (46.18% growth)
  • Earnings Per Share: Basic ₹18.33, Diluted ₹18.29

Key Financial Ratios

  • Operating Profit Margin: 5.74% (improved from 4.66% in FY25)
  • Net Profit Margin: 3.19% (improved from 2.45% in FY25)
  • Return on Net Worth: 11.82% (improved from 9.06% in FY25)
  • Inventory Turnover: 73.17 days (improved from 80.01 days)
  • Current Ratio: 3.00 (slight decrease from 3.20)

Operational Performance

Store Network Expansion

The company added 618 net new stores during FY25-26, significantly higher than the 305 stores added in the previous year. Total store count reached 5,330 stores, demonstrating aggressive expansion strategy.

Business Segments

  • Retail Segment: ₹67,601.06 million (98.10% of revenue)
  • Diagnostic Services: ₹1,309.87 million (1.90% of revenue)
  • Private Label Contribution: 21.88% of consolidated revenue (up from 19.29%)

ESG Performance

Environmental Indicators:

  • Greenhouse gas emissions intensity: 0.51 MTCO2e/₹ million revenue
  • Total waste generated: 1,951.48 metric tonnes with 72.3% recycling rate
  • Waste management initiatives included phasing out single-use plastic bags and promoting reusable alternatives

Social Indicators:

  • 100% domestic sourcing of inputs
  • 8.93% of input materials sourced from MSMEs
  • CSR spending of ₹18.87 million meeting mandatory 2% requirement
  • 15 CSR projects benefiting 16,811 persons from vulnerable groups

Corporate Governance & Leadership

Board Changes

The 20th Annual General Meeting is scheduled for August 17, 2026, to adopt financial statements and address several appointments:

  • Appointment of Mr. Mohan Krishna Reddy as Independent Director (May 2026 to May 2031)
  • Appointment of Mr. Ajit Pandurang Rangnekar as Independent Director (May 2026 to May 2031)
  • Re-appointment of Mr. Gangadi Madhukar Reddy as Managing Director & CEO for five years from August 2026

Shareholding Structure

  • Promoter Holding: 40.22% (G. Madhukar Reddy 12.79%, Agilemed Investments 13.04%, Lone Furrow Investment 14.39%)
  • Institutional Holding: Nippon Life India Trustee Limited 7.54%
  • Public Holding: 59.78%

Regulatory Compliance & Audits

The company maintained full regulatory compliance with unqualified audit opinions from B S R & Co. on both standalone and consolidated financial statements. All statutory auditors' reports contained no qualifications, reservations, or adverse remarks.

Capital Structure & Utilization

  • Paid-up Equity Share Capital: ₹240.11 million (120,054,642 equity shares of ₹2 each)
  • IPO Proceeds: Fully utilized ₹5,789.33 million for working capital investment in Optival Health Solutions (₹4,671.70 million) and general corporate purposes (₹1,117.63 million)
  • Debt Position: Zero debt as of March 31, 2026

Risk Management

The company identified and mitigated various risks including intense competition, regulatory compliance, supply chain management, cybersecurity, and operational risks. Comprehensive risk management frameworks are in place across all operations.

Forward Outlook

MedPlus remains committed to cluster-based expansion and private label growth while maintaining focus on providing genuine products, unparalleled convenience, and competitive pricing. The company continues to invest in sustainability initiatives and regulatory compliance across all business segments.